XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > SpaceLab and CandyC - The toxic retail investor

<< Previous

Bullboard Posts

Next >>

Comment by vitalina2233on Sep 16, 2021 11:29am

103 Views

Post# 33868487

RE:RE:RE:RE:RE:SpaceLab and CandyC - The toxic retail investor

I also suffer from gout, by the toe. Painfull doesn't descibe it to say the least. I wish the best for your health . Once you got got ,its with you for life. A have a large position as well and added another 20k at .59 today. I truely have all the faith in this stock Stay well Gold Papi

<< Previous

Bullboard Posts

Next >>

Top 10 pharmaceutical AI stocks